Abcam, ab259223, Human UBE2J1 (UBC6e) knockout HeLa cell lysate

Size: 1Kit
UBE2J1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 8 bp deletion in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 8 bp deletion in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-UBE2J1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBC6e also known as UBE2J2 is a ubiquitin-conjugating enzyme with a molecular mass of approximately 33 kDa. It resides within the membrane of the endoplasmic reticulum (ER) where it functions as an E2 enzyme. UBC6e facilitates the transfer of ubiquitin from E1 activating enzymes to substrate proteins signaling these proteins for degradation. This enzyme's role is essential for controlling protein quality preventing accumulation of misfolded proteins within the ER.
Biological function summary
UBC6e contributes significantly to the ER-associated degradation (ERAD) pathway. The protein operates as part of a larger complex that identifies and targets defective proteins for ubiquitination and subsequent breakdown. Its activity maintains cellular homeostasis by regulating the protein landscape in the ER. The presence of UBC6e ensures only properly folded proteins proceed to the Golgi apparatus reducing the potential for cellular malfunction due to protein misfolding.
Pathways
UBC6e plays a critical role in the unfolded protein response (UPR) and proteostasis networks. The UPR pathway involves proteins like IRE1 and ATF6 working with UBC6e to alleviate ER stress by degrading misfolded proteins. Another pathway related to UBC6e is the proteasome degradation pathway which relies on activities like those of UBC6e and other E2 enzymes to clear misfolded proteins. Together these pathways help the cell manage stress and adapt to environmental changes.
UBC6e has connections with neurodegenerative diseases and certain types of cancer. Its involvement in ERAD relates it to diseases like Alzheimer's where protein misfolding and aggregation are problematic. Furthermore alterations in UBC6e activity intersect with proteins like p53 linking it to cancer progression. Dysregulation of ubiquitination involving UBC6e may contribute to both disease states highlighting its potential as a target for therapeutic intervention.